US trials show single dose of coronavirus vaccine

US, WASHINGTON (ORDO NEWS) — Moderna Coronavirus Vaccine Test Results Revealed In USA It turned out that the drug does not lead to a more severe course of the disease, and even a single dose can protect against COVID-19.

Preliminary tests of the coronavirus vaccine, conducted by the American company Moderna, showed that it does not increase the risk of a more severe course of the disease. In addition, even a single dose of the drug can protect against infection, according to the bioRxiv scientific portal.

Experts conducted tests on mice. They concluded that the vaccine protects the lungs with no signs of toxicity. Prior to obtaining the results, the company’s specialists called possible complications during the illness the main obstacle to safe drug testing in humans. This is exactly what happened during the SARS vaccine test, which causes SARS.

During a new study, Moderna experts injected mice with the drug once or twice. They also used doses that are considered not strong enough to induce protective immunity. As a result, their fears about a possible severe course of the disease were not confirmed, and even one dose could cope with the protection against the virus. But this does not mean that when testing the drug in humans, the results will be the same, scientists say.

The company intends to conduct the final stage of testing in July. At this stage, 30,000 people will participate.

In May, the head of Rospotrebnadzor, Anna Popova, said that part of the restrictions imposed in Russia would remain in effect until the vaccine against coronavirus. She noted that this period could last until the end of the year. According to the Minister of Health Mikhail Murashko, several vaccines may appear simultaneously in Russia, each of which will have its own temporary period of protection. “It remains to be assessed how long specific immunity will remain after vaccination,” the head of the Ministry of Health said.


Contact us: [email protected]

Our Standards, Terms of Use: Standard Terms And Conditions.